

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 September 2024 (06.09.2024)



(10) International Publication Number
WO 2024/182404 A1

(51) International Patent Classification:

C07D 211/96 (2006.01) A61P 37/00 (2006.01)
A61K 31/445 (2006.01) A61P 17/02 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/017497

(22) International Filing Date:

27 February 2024 (27.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/487,431 28 February 2023 (28.02.2023) US

(71) Applicant: **VIVIDION THERAPEUTICS, INC**
[US/US]; 5820 Nancy Ridge Dr., San Diego, California
92121 (US).

(72) Inventors: **TAMIYA, Junko**; 5820 Nancy Ridge Dr., San
Diego, California 92121 (US). **HORNING, Benjamin**;
5820 Nancy Ridge Dr., San Diego, California 92121 (US).
BEDKE, Karl; 5820 Nancy Ridge Dr., San Diego, Cali-
fornia 92121 (US). **BERRY, Cynthia**; 5820 Nancy Ridge
Dr., San Diego, California 92121 (US). **PAN, Chung-Mao**;
5820 Nancy Ridge Dr., San Diego, California 92121 (US).
ONDOZABAL, Hideki Miyatake; 5820 Nancy Ridge Dr.,
San Diego, California 92121 (US). **COOK, Brian**; 5820
Nancy Ridge Dr., San Diego, California 92121 (US).

(74) Agent: **HANSEN, Christine M.**; Quarles & Brady LLP,
135 N. Pennsylvania Street, Suite 2400, Indianapolis, Indi-
ana 46204 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))


Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))



WO 2024/182404 A1

(54) Title: 1-(((1, 1'-BIPHENYL]-2-YL)SULFONYL)-4-FLUORO-N-(3-(METHYLSULFONYL)ALLYL)PIPERIDINE-4-CAR-
BOXAMIDE DERIVATIVES AS RAS-PI3K MODULATORS FOR THE TREATMENT OF E.G. CANCER



Formula (I)

(57) Abstract: The present invention relates to compounds of formula (I) as RAS-PI3K modulators for use in
methods of treatment of cancer, immunological disorders and wound healing. Preferred compounds are e.g. 1-
(((1,1'-biphenyl]-2-yl)sulfonyl)-4-fluoro-N-(3-(methylsulfonyl)allyl)piperidine-4-carboxamide derivatives.